Recent Updates
Recently added Catalysts

CR-001

Phase 1/2

Locally Advanced / Metastatic Solid Tumors | Biologics | Oncology |Crescent Biopharma, Inc.|Trials Updated: Nov 13, 2026

CR-001 development status

Highest phase Phase 1/2
Registered trials 1 across 1 sponsor since Jan 2026

CR-001 target and mechanism

Molecular targetPD-1
Target classProtein
ModalityBiologics

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

CONTROLLED
Total Trials1
Total Enrollment540

FDA Designations

No designations recorded

CR-001 clinical trials

CR-001 · 1 trial · 1 indication

Phase 1/2 1
NCT07335497CR-001 in Adult Participants With Locally Advanced or Metastatic Solid TumorsLocally Advanced / Metastatic Solid Tumors
RECRUITING540 Analytics
PHASE1/PHASE2RECRUITING
CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
Locally Advanced / Metastatic Solid TumorsUnlock trial analytics

Study Endpoints

Primary Endpoints

Part 1 (Dose Escalation) - Incidence and nature of dose-limiting toxicities
From the first dose of study drug up until approximately 1 month

Per cohort

Part 1 (Dose Escalation) - Characterization of the maximum tolerated dose, if applicable
From the first dose of study drug up until approximately 1 month

Per Cohort

All parts - Incidence, nature, and severity of treatment emergent adverse events (TEAEs) and treatment - emergent serious adverse events
From the first dose of study drug until 90 days after the last dose of study drug

Events graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)

All parts - Incidence and severity of TEAEs leading to dose modifications
From the first dose of study drug until 90 days after the last dose of study drug
All parts - Incidence and severity of TEAEs leading to treatment discontinuation
From the first dose of study drug until 90 days after the last dose of study drug
Part 3 (Dose Expansion) - Overall response rate (ORR) by Investigator assessment per Response Evaluation Criteria in Solid Tumors (RECIST v1.1)
From the first dose of study drug until 90 days after the last dose of study drug

Secondary Endpoints

All parts - Determination of recommended Phase 2 dose(s)
From the first dose of study drug until 90 days after the last dose of study drug
All parts - Serum CR-001 pharmacokinetic parameters
Predose until up to approximately 36 months
All parts - Incidence of participants with detectable antidrug antibodies
Predose until up to approximately 36 months
Unlock Study Endpoints

Study Design & Arms

AllocationNON_RANDOMIZED
MaskingNONE
ModelSEQUENTIAL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
CR-001 Dose escalationEXPERIMENTALEscalating dose levels of CR-001 to define the maximum tolerated dose of CR-001 in participants with locally advanced or metastatic solid tumors who are refractory to or unable to tolerate standard of care treatment, or for whom standard of care treatment is unavailable
CR-001 BackfillEXPERIMENTALEscalating dose levels of CR-001 Indication-specific cohort populations will be tested
CR-001 Dose Expansion 3A: First-line (1L) Non-small cell lung cancerEXPERIMENTALCR-001 in combination with paclitaxel or pemetrexed + carboplatin
CR-001 Dose Expansion 3B: First-line (1L) colorectal cancerEXPERIMENTALCR-001 in combination with FOLFOX
CR-001 Dose Expansion 3C: Third-line (3L) colorectal cancerEXPERIMENTALCR-001 in combination with trifluridine + tipiracil
CR-001 Dose Expansion 3D: First-line (1L) endometrial carcinomaEXPERIMENTALCR-001 in combination with paclitaxel + carboplatin
CR-001 Dose Expansion 3E: First-line (1L) gastric/gastroesophageal cancerEXPERIMENTALCR-001 in combination capecitabine + oxaliplatin
CR-001 Dose Expansion 3F: Second-line (2L) gastric/gastroesophageal cancerEXPERIMENTALCR-001 in combination with paclitaxel
CR-001 Dose Expansion 3G: First-line (1L) Biliary tract cancerEXPERIMENTALCR-001 in combination with gemcitabine + cisplatin
CR-001 Dose Optimization Cohort XEXPERIMENTALmonotherapy dose level (DL)-X Indication-specific cohort populations will be tested
CR-001 Dose Optimization Cohort YEXPERIMENTALmonotherapy dose level (DL)-Y Indication-specific cohort populations will be tested

Interventions

NameTypeDescription
CR-001DRUGIntravenous Infusion
PaclitaxelDRUGIntravenous Infusion
trifluridine and tipiracilDRUGOral
PemetrexedDRUGIntravenous Infusion
CarboplatinDRUGIntravenous Infusion
OxaliplatinDRUGIntravenous Infusion
GemcitabinDRUGIntravenous Infusion
CisplatinDRUGIntravenous Infusion
CapecitabineDRUGOral
FOLFOXDRUGIntravenous Infusion + Oral
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites36

Key Inclusion Criteria * Life expectancy ≥ 3 months * Eastern Cooperative Oncology Group (ECOG) performance status score of 0 - 1 * Adequate organ function and hematologic reserve based on laboratory parameters * Have measurable disease defined by RECIST v1.1 * For Backfill, Dose Expansion and Dose...

Countries:United StatesAustraliaFranceIrelandItalyRomaniaSouth KoreaSpainUkraineUnited Kingdom
Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

LOWNov 13, 2026NCT07335497lastUpdatePostDate: changed
LOWNov 13, 2026NCT07335497lastUpdatePostDate: changed
MEDIUMOct 20, 2026NCT07335497Enrollment: 290 → 540
MEDIUMOct 20, 2026NCT07335497Enrollment: 290 → 540
LOWSep 10, 2026NCT07335497lastUpdatePostDate: changed
LOWSep 10, 2026NCT07335497lastUpdatePostDate: changed
LOWSep 1, 2026NCT07335497lastUpdatePostDate: changed
LOWSep 1, 2026NCT07335497lastUpdatePostDate: changed

Frequently asked questions about CR-001

What is CR-001?

CR-001 is an investigational biologic developed by Crescent Biopharma, Inc. for locally advanced or metastatic solid tumors. It is in Phase 1/2 clinical development in oncology and is being studied in adult participants with advanced solid tumors across multiple countries.

What is CR-001 used for?

CR-001 is being studied for the treatment of locally advanced or metastatic solid tumors. It is an oncology asset in Phase 1/2 development and is not yet established as a treatment outside clinical research. The ongoing study enrolls adults aged 18 years and older.

What does CR-001 target?

CR-001 targets PD-1, a protein target. PD-1 is a checkpoint receptor on immune cells, and agents directed at it are designed to act on PD-1 mediated signaling. CR-001 is a biologic in Phase 1/2 development for locally advanced or metastatic solid tumors.

Who is developing CR-001?

CR-001 is being developed by Crescent Biopharma, Inc., which trades under the ticker CBIO. The company is running the Phase 1/2 program in locally advanced or metastatic solid tumors, with the study currently recruiting participants across the United States, Europe, Australia, and South Korea.

What phase is CR-001 in?

CR-001 is in Phase 1/2 clinical development. It is an investigational agent and is not described as FDA approved. The single ongoing trial is a Phase 1/Phase 2 study that is currently recruiting, with planned enrollment of 540 participants.

What clinical trial is CR-001 in?

CR-001 is being studied in trial NCT07335497, titled CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors. The Phase 1/Phase 2 study is recruiting, is controlled, is not randomized or double blinded, and plans to enroll 540 adults across ten countries.

Is CR-001 the same as 001?

Yes, CR-001 is also known as 001. Both names refer to the same investigational biologic from Crescent Biopharma, Inc. (ticker CBIO) that targets PD-1 and is in Phase 1/2 development for locally advanced or metastatic solid tumors.